Navigation Links
Novel discovery by NUS scientists paves the way for more effective treatment of cancers
Date:5/21/2012

A team of scientists from the National University of Singapore's (NUS) Department of Biological Sciences and Mechanobiology Institute have discovered how a drug-led compound a compound that is undergoing preclinical trials as a potential drug can deprive cancer cells of energy and stop them from growing into a tumour. This drug-led compound is named BPTES.

This is the first time a research group has provided evidence showing how a drug-lead compound suppresses tumour formation.

Building on the new findings, the NUS team also derived positive results for a novel dual-drug treatment regime involving BPTES that kills kidney and breast cancer cells more effectively.

The team led by Associate Professor Low Boon Chuan and Associate Professor Jayaraman Sivaraman first published their findings in the journal of Proceedings of the National Academy of Sciences (PNAS) on 26 April 2012.

Killing cancer cells by 'starving' them of energy

Classic experiments in cancer biology have demonstrated that cancer cells feed off the breakdown of the amino acid glutamine to gain energy and grow into a tumour. While it is known that human glutaminase is the first enzyme in catalysing this series of biochemical reactions, little is known about how its activity is controlled, and how it can be manipulated.

The NUS research team has successfully identified the mechanism in which the BPTES that can bind and inhibit glutaminase, can effectively starve the cancer cells of their energy source, and hence, could potentially prevent tumour growth.

In addition, the team has also found that the glutaminase activity can be activated upon the addition of phosphate by epidermal growth factor signaling a pathway that controls cancer cells proliferation. By using another inhibitor to block the kinase Mek2 within this cancer-causing pathway, coupled with the use of BPTES, the combined therapeutic effect is more potent and less toxic. This raises the hope of offering a new dual-drug cancer treatment regime for cancers such as lymphoma, prostate, glioblastoma, breast and kidney cancer cells that is more effective and with fewer side-effects.

The Next Step

Armed with structural insights into the binding and signaling pathway that activates glutaminase, the NUS research team is conducting more studies to determine whether a combination of drugs would be even more effective in inhibiting glutaminase activity and hence, tumour formation.

Using the knowledge that they gained through their current studies, the research team will also look into optimising the tumour suppression property of BPTES to increase its efficiency and lower its side-effects.


'/>"/>
Contact: Carolyn Fong
carolyn@nus.edu.sg
65-651-65399
National University of Singapore
Source:Eurekalert

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics ... biotherapeutics development, announces the launch of the new NHS Agile biosensor chip ... binding data for a wide range of molecules, including small and large molecules, ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... of 6” modular downlights designed to stay tightly sealed and perform efficiently for ... damp and wet location listings just aren't enough, such as: hospitals; behavioral health ...
(Date:8/15/2017)... ... 2017 , ... JULABO USA introduces its new website ... it easy to navigate through the site whether you’re in the office, in ... educational industry content and visit the company’s social media accounts, all on one ...
(Date:8/14/2017)... ... 2017 , ... The Conference Forum has confirmed the one-day agenda ... September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning as ... Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in discussing ...
Breaking Biology Technology: